Examining Predictors of Vaccine Trial Engagement Outcomes among Sexual and Gender Minority LatinX Communities through an Explanatory Mixed Methods Design

COVID-19大流行同时凸显了mRNA疫苗的潜力和现实 疫苗犹豫和健康不平等的特定社区，如拉丁裔人口。Latinx 在针对COVID-19的mRNA疫苗试验中， 在以前的临床试验中代表性不足。这限制了我们对疫苗接种活动的理解， 拉丁裔社区在这一点上，LatinX人群不太可能接种COVD-19疫苗， 比非拉丁裔白色人群更有可能死于COVID-19。拉丁裔人口在 移民身份，种族，主要语言，原籍国和社会经济地位，但我们有限 了解这些因素如何影响拉丁美洲的临床试验参与或疫苗犹豫 人口。mRNA疫苗试验也开始解决不成比例地影响女同性恋的病毒， 同性恋、双性恋和跨性别人群，如艾滋病毒和疱疹。LatinX LGBT人群面临 男女同性恋、双性恋和变性者群体之间的健康差距更大。然而，很少有研究关注拉丁裔LGBT 临床试验的经验或看法，如mRNA疫苗试验。对于mRNA技术来说， 在LGBT和LatinX社区解决病毒的全部潜力，重要的是要检查临床试验 在种族/族裔、性和性别的关键时刻参与。建议的主要目标 一项研究旨在确定在LGBT拉丁裔人群中提高mRNA疫苗试验参与公平性的机会 人口通过解释性混合方法的方法。现有的团队在LGBT和 拉丁健康差异（佛罗里达州立大学健康公平人口科学中心） 护理学院）和当地社区合作伙伴，为LGBT拉丁裔人口在棕榈县， 佛罗里达（指南针）提出了一个解释性的混合方法研究，以解决疫苗试验的参与， mRNA的看法，移民背景，以及可能的相关因素之间的LGBT LatinX人群。 拟议的U 01研究将通过两个阶段解决疫苗试验参与不公平问题：（1）确定亚组， 与参与mRNA疫苗临床试验的兴趣降低相关的群体特征 南佛罗里达的LatinX LGBT人群（N = 600，300名第一代移民，300名2+代），以及（2） 了解临床试验参与兴趣降低的原因，并收集可能的观点 使用定性深入访谈（N = 60）增加参与的途径。调查结果将用于 确定增加LGBT LatinX参与mRNA疫苗试验和临床的公平性的可能途径 审判范围更广。

The COVID-19 pandemic simultaneously highlights the potential for mRNA vaccines as well as the realities of vaccine hesitancy and health inequity among specific communities such as LatinX populations. LatinX populations were underrepresented in mRNA vaccine trials for COVID-19 much like they have been underrepresented in clinical trials previously. This limits our understanding of vaccine campaign rollout in Latinx communities. To this point LatinX populations were less likely to be vaccinated against COVD-19 and more likely to die from COVID-19 than non-LatinX white populations. LatinX populations are diverse in regard to immigration status, race, primary language, nation of origin, and socio-economic status, yet we have limited understandings of how these factors impact clinical trial participation or vaccine hesitancy in LatinX populations. mRNA vaccine trials are also starting to address viruses that disproportionately impact lesbian, gay, bisexual, and transgender (LGBT) populations such as HIV and herpes. LatinX LGBT populations face greater health disparities among LGBT populations. Yet very little if any research has focused on LatinX LGBT experiences or perceptions of clinical trials such as mRNA vaccine trials. For mRNA technologies to reach their full potential for addressing viruses in LGBT and LatinX communities it is important to examine clinical trial participation at the critical juncture of race/ethnicity, sexuality, and gender. The primary goal of the proposed study is to identify opportunities for improved equity in mRNA vaccine trial participation among LGBT LatinX populations through an explanatory mixed-methods approach. An existing team well-established in LGBT and Latinx health disparities (the Center of Population Sciences for Health Equity in Florida State University’s College of Nursing) and a local community partner that serves LGBT LatinX populations in Palm County, Florida (Compass) proposes an explanatory mixed-methods study to address vaccine trial participation, perceptions of mRNA, immigration background, and possible related factors among LGBT LatinX populations. The proposed U01 study will address vaccine trial participation inequities through two phases: (1) identify sub- group characteristics associated with reduced interest in mRNA vaccine clinical trial participation in a sample of LatinX LGBT people in South Florida (N = 600, 300 first generation immigrants, 300 2+ generation), and (2) Understand reasons for reduced interest in clinical trial participation and collect perspectives on possible avenues for increasing participation using qualitative in-depth interviews (N = 60). Findings will be used to identify possible avenues of increasing equity in LGBT LatinX participation in mRNA vaccine trials and clinical trials more broadly.